Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

68.16 USD -0.21 (-0.31%)
Streaming Delayed Price Updated: 2:36 PM EDT, Jul 29, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Arrowhead Pharma

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Arrowhead receives breakthrough therapy designation for ARO-AAT and announces full enrollment for SEQUOIA Phase 2 clinical trial 
From Business Wire News Releases
7 Best ETFs to Buy That Will Make Your World a Better Place
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to innovation and making your world a better place, these are the best ETFs to buy to meet your objectives while making... 
Tags HTEC GINN NOW
From InvestorPlace
First Week of March 2022 Options Trading For Arrowhead Pharmaceuticals
Investors in Arrowhead Pharmaceuticals Inc (ARWR) saw new options become available this week, for the March 2022 expiration. One of the key data points that goes into the price an option buyer is... 
Tags Stocks
From Market News Video
Arrowhead Pharmaceuticals: Buy the Dip?
This biotech underdog offers more than meets the eye. 
Tags TKPHF ARWR JNJ
From Motley Fool
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
From Business Wire News Releases
Russell 2000 Traders Place Bearish Bets Via IWM ETF
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last sixmonths between $211 and its ... 
Tags Top Stories OVV CROX
From Benzinga
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead PharmaceuticalsInc(NASDAQ: ARWR)tied to the ARO-EnAC phase 1/2 study halt is ... 
Tags Market News Health Care Benzinga
From Benzinga
IWM, NTLA, ARWR, LSCC: ETF Outflow Alert
Symbols mentioned in this story: IWM, NTLA, ARWR, LSCC Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer
Arrowhead Pharmaceuticals Inc(NASDAQ: ARWR)has announced interim resultsfrom the first two cohorts of Phase 1b ... 
Tags Briefs News ARWR
From Benzinga
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Arrowhead announced positive interim results on RNAi investigational medicine ARO-HIF2 in patients with renal cell carcinoma 
From Business Wire News Releases
56 Biggest Movers From Friday
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) ... 
Tags AESE News MRIN
From Benzinga
Noteworthy Friday Option Activity: OPRX, ARWR, TWOU
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in OptimizeRx Corp (OPRX), where a total volume of 2,961 contracts has been traded... 
Tags Stocks
From Market News Video
Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, ... 
Tags ARWR Market News Benzinga
From Benzinga
S&P 500 Logs Another Record High as "Fear Gauge" Dips
Stocks are modestly in the black midday, thanks to upbeat monthly jobs data that showed 850,000 jobs were added in June. 
Tags Stocks / Equities Market News
From Blogs - TalkMarkets
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. ... 
Tags ATOS ATHE BZI/TFM
From Benzinga
Arrowhead Stock Plunges, Alector Stock Surges On Drug News
Arrowhead paused a study of a cystic fibrosis drug while Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged. 
From Investor's Business Daily
Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, ... 
Tags ITRM WAVE Penny Stocks
From Benzinga
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
A paused clinical trial with an important asset wasn't what investors wanted to hear today. 
Tags ARWR Market News ALNY
From Motley Fool
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market ... 
Tags ASRT KTRA Market News
From Benzinga
Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models
Arrowhead Pharmaceuticals Inc(NASDAQ: ARWR)has voluntarily pausedthe AROENaC1001 Phase 1/2 study evaluating ... 
Tags FDA Short Ideas Market News
From Benzinga
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study 
From Business Wire News Releases
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-ANG3 an RNAi therapeutic to treat mixed dyslipidemia 
From Business Wire News Releases
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
Arrowhead and Takeda presented positive clinical trial data on rare orphan disease RNAi drug ARO-AAT at EASL The International Liver Congress 
From Business Wire News Releases
Notable ETF Outflow Detected - IWO, RH, DECK, ARWR
Symbols mentioned in this story: IWO, RH, DECK, ARWR Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''... 
Tags ETFs
From ETF Channel
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Arrowhead Pharmaceuticals presented preclinical data on the development of ARO-DUX4 at 28th Annual FSHD Society International Research Congress 
From Business Wire News Releases
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags RMD ENTX IRWD
From Benzinga
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Arrowhead presents data at EASL showing ARO-HSD reduces HSD17B13 mRNA and protein in the liver leading to reductions in ALT 
From Business Wire News Releases
Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate
Arrowhead Pharmaceuticals Inc(NASDAQ: ARWR) andHorizon Therapeutics plc(NASDAQ: HZNP) have entered into ... 
Tags Contracts Briefs News
From Benzinga
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Arrowhead Pharmaceuticals and Horizon Therapeutics collaborate on RNAi therapeutic for uncontrolled gout 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.